A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis.
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis.
- drug : Placebo
- drug : BAF312
Phase: Phase 3
Ages Eligible For Study:
- Prior history of relapsing remitting MS - SPMS defined as progressive increase of disability over at least 6 months - EDSS score of 3.0 to 6.5 - No relapse of corticosteroid treatment within 3 months